2020 / 01

Next Paper
DOI: 10.24075/brsmu.2020.003

ORIGINAL RESEARCH

Efficiency of the gynecologic malignancies identification measures at the level of primary health care

Bochkova AG, Domozhirova AS, Aksenovа IA1,3
About authors

1 South Ural State Medical University, Chelyabinsk, Russia

2 Russian Scientific Center for Roentgenoradiology, Moscow, Russia

3 Clinical Center of Oncology and Nuclear Medicine of Chelyabinsk Region, Chelyabinsk, Russia

Correspondence should be addressed: Anna G. Bochkova
Dovatora, 23, Chelyabinsk, 454091; ur.liam@6947avokhcobanna

About paper

Author contribution: Bochkova AG — research planning, manuscript writing, data acquisition, data analysis and interpretation, literature analysis; Domozhirova AS — research planning, data analysis and interpretation, manuscript editing; Aksenovа IA — data acquisition, manuscript writing.

Received: 2019-12-23 Accepted: 2020-01-08 Published online: 2020-01-23
|
Fig. 1. Dynamics of the I/II stage cervical cancer (C53) proportion in patients identified actively in the patient examination rooms compared with the average rate for Chelyabinsk Region in 2010-2017, %
Fig. 2. Dynamics of the I/II stage uterine corpus cancer (С54) proportion in patients identified actively in the patient examination rooms compared with the average rate for Chelyabinsk Region in 2010–2017, %
Fig. 3. Dynamics of the I/II stage ovarian cancer (С56) proportion in patients identified actively in the patient examination rooms compared with the average rate for Chelyabinsk Region in 2010–2017, %
Fig. 4. Adjusted cumulative survival in cervical cancer patients (С53) of the treatment and control groups (PBCR of the Chelyabinsk Region database, 2005–2015), %
Fig. 5. Adjusted cumulative survival in uterine corpus cancer patients (С54) of the treatment and control groups (PBCR of the Chelyabinsk Region database, 2005–2015), %
Fig. 6. Adjusted cumulative survival in ovarian cancer patients (С56) of the treatment and control groups (PBCR of the Chelyabinsk Region database, 2005–2015), %
Table 1. Stage distribution in cervical cancer patients (С53) of the treatment and control groups according to the FIGO system (2009)
Table 2. Stage distribution in uterine corpus cancer patients (С54) of the treatment and control groups according to the FIGO system (2009)
Table 3. Stage distribution in ovarian cancer patients (С56)of the treatment and control groups according to the FIGO system (2009)